You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Fresh Pfizer-BioNTech data shows coronavirus vaccine easier to use

Fresh Pfizer-BioNTech data shows coronavirus vaccine easier to use

Topics
Pfizer | Coronavirus Vaccine

AP  |  New York 

Pfizer, coronavirus vaccine

New data indicate the COVID-19 vaccine developed by and German partner BioNTech could be stored for two weeks without the ultracold storage currently required, potentially making its use a bit easier.

The companies said Friday they've submitted findings from ongoing stability testing to the US Food and Drug Administration, which has authorised the vaccine's emergency use in the US, and will send the data to regulators around the world in the next few weeks.

The companies want regulators to update temperature requirements to state the vaccines can maintain their potency for two weeks if kept at -13F to 5F (-25C to -15C), as an additional option.

Freezers and refrigerators used in many pharmacies and hospitals commonly chill to those temperatures but not to the temperature range

currently authorised, from -112F to -76F (-80C to -60C). The vaccine can remain stable at those temperatures for up to six months.

That's why New York-based and BioNTech ship the vaccine vials in special thermal containers that can serve as temporary storage for up to 30 days by repeatedly adding dry ice.

Still, that can make storing and then thawing and administering the two-dose vaccine challenging in many places, particularly developing countries.

The companies have been testing stability of vaccine batches manufactured at different times over the past nine months and continue to research ways to boost the vaccine's shelf life.

If approved, this new storage option would offer pharmacies and vaccination centers greater flexibility in how they manage their vaccine supply, Chief Executive Albert Bourla said in a statement.

The shot is one of just two vaccines that have emergency use authorization in the U.S., though a third vaccine, created by Johnson and Johnson, is expected to win FDA clearance for emergency use within two weeks.

The other vaccine now authorized in the U.S., made by Moderna, started out with similarly cold temperature requirements in early-stage studies before stability testing showed it could be stored at normal freezer temps.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, February 19 2021. 23:52 IST
RECOMMENDED FOR YOU